Invesco Ltd‘s “Small Cap Value Fund” released its Q4 2025 investor letter. A copy of the letter can be downloaded here. The Invesco Small Cap Value Fund reported strong results for Q4 2025, outperforming its Russell 2000 Value Index benchmark as Class A shares delivered a quarterly return of 6.79%, compared to the benchmark’s 3.26%, with stock selection in the Information Technology sector contributing approximately 2.90% to relative performance while health care and financials detracted. For the full year, the fund generated a 17.64% return versus 12.59% for the Russell 2000 Value Index. Management maintained greater exposure to economically sensitive stocks and emphasized that small-cap value equities remain attractively priced, noting that the Russell 2000 Value Index continues to trade at a historical P/E discount relative to the S&P 500, indicating compelling long-term capital appreciation potential. In addition, please check the Fund’s top five holdings to know its best picks in 2025.
In its fourth-quarter 2025 investor letter, Invesco Small Cap Value Fund highlighted stocks like Globus Medical, Inc. (NYSE:GMED). Globus Medical, Inc. (NYSE:GMED) is a medical device company that develops musculoskeletal solutions, including spinal implants and surgical technologies. The one-month return of Globus Medical, Inc. (NYSE:GMED) was 2.83% while its shares traded between $51.79 and $101.40 over the last 52 weeks. On March 04, 2026, Globus Medical, Inc. (NYSE:GMED) stock closed at approximately $90.46 per share, with a market capitalization of about $12.17 billion.
Invesco Small Cap Value Fund stated the following regarding Globus Medical, Inc. (NYSE:GMED) in its Q4 2025 investor letter:
“Globus Medical, Inc. (NYSE:GMED): This medical technology company specializes in musculoskeletal solutions for spine, orthopedic trauma and joint reconstruction. The company has faced issues with recent acquisitions, supply chain issues and weakness in its robotics segment, which together provided an opportunity to purchase the stock at what we saw as an attractive discount to our estimate of intrinsic value.”
Globus Medical, Inc. (NYSE:GMED) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. As per our database, 42 hedge fund portfolios held Globus Medical, Inc. (NYSE:GMED) at the end of the fourth quarter, which was 46 in the previous quarter. While we acknowledge the risk and potential of Globus Medical, Inc. (NYSE:GMED) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Globus Medical, Inc. (NYSE:GMED) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Globus Medical, Inc. (NYSE:GMED) and shared the list of best medical technology stocks to invest in. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. This article is originally published at Insider Monkey.
